Renalytix (LON:RENX) Insider Christopher Mills Sells 1,166,667 Shares of Company Stock

Renalytix Plc (LON:RENX) insider Christopher Mills sold 1,166,667 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of GBX 6, for a total value of £70,000.02.

Renalytix Stock Performance

RENX traded up GBX 0.04 on Thursday, reaching GBX 6.14. The company had a trading volume of 1,187,215 shares, compared to its average volume of 1,100,340. The company has a quick ratio of 2.42, a current ratio of 1.57 and a debt-to-equity ratio of -483.33. Renalytix Plc has a 1 year low of GBX 1.60 and a 1 year high of GBX 10. The stock has a 50-day moving average price of GBX 4.47 and a 200-day moving average price of GBX 2.93. The stock has a market capitalization of £26.85 million, a PE ratio of -1.54 and a beta of 1.81.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).